Literature DB >> 35291415

Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease.

Mohammad Hatampour1, Karim Sohrabi2, Hamid Mazdak3, Keyvan Ghadimi1, Hanieh Salehi1, Reza Kazemi3.   

Abstract

BACKGROUND: Some studies demonstrated the effect of the combination of modalities in Peyronie's disease (PD) therapy; however, there is no comprehensive study for evaluation of dexamethasone and phosphodiesterase type 5 (PDE5) inhibitors such as tadalafil in the treatment of PD, so the study aimed to evaluate the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the patients with PD.
MATERIALS AND METHODS: This double-blinded randomized, controlled trial was conducted on the patients with PD referred to Alzahra and Khorshid hospitals, Isfahan, Iran. Then the patients were randomly divided into two groups as intervention and control groups. In the intervention group, tadalafil (5 mg PO) was administered once daily for 12 weeks and dexamethasone (8 mg) was injected once a week for 12 weeks. In the control group, the verapamil (5 mg: 2 cc) was injected once a week for 12 weeks. Before and after 12 weeks, an ultrasound was performed to assess the size, number and location of the plaque. The degree of penile curvature from the midline, dorsal and lateral curvature was also determined.
RESULTS: The means of penis curvature in the intervention and control groups before therapy were 34.09±7.05˚ and 31.09±7.06˚, respectively (P=0.097) and also after therapy were 27.3±7.79˚ and 24.6±6.64˚, respectively (P=0.13). The means of plaque count in the intervention and control groups before treatment were 2.0±1.03 and 1.96±1.06, respectively (P=0.9) and after treatment were 1.22±0.71 and 1.40±0.79, respectively (P=0.34). The means of plaque size in the intervention and control groups were 12.31±4.9 cm and 12.45±4.12 cm, respectively (P=0.9) and after intervention 7.8±3.08 and 9.03±3.46 cm, respectively (P=0.15).
CONCLUSION: According to these findings, there was no significant difference between intervention and control groups regarding the degree of penis curvature, and the count and size of the plaque. Therefore, it seems that tadalafil therapy with dexamethasone did not improve PD compared to verapamil. AJCEU
Copyright © 2022.

Entities:  

Keywords:  Dexamethasone; Peyronie’s disease; tadalafil

Year:  2022        PMID: 35291415      PMCID: PMC8918397     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  21 in total

Review 1.  Erectile dysfunction.

Authors:  T F Lue
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

2.  Massive Transfusion Protocols in Obstetric Hemorrhage: Theory versus Reality.

Authors:  Bahram Salmanian; Steven L Clark; Shiu-Ki R Hui; Sarah Detlefs; Soroush Aalipour; Nazlisadat Meshinchi Asl; Alireza A Shamshirsaz
Journal:  Am J Perinatol       Date:  2021-05-14       Impact factor: 1.862

3.  A surgical algorithm for men with combined Peyronie's disease and erectile dysfunction: functional and satisfaction outcomes.

Authors:  John Mulhall; Matthew Anderson; Marilyn Parker
Journal:  J Sex Med       Date:  2005-01       Impact factor: 3.802

4.  Measurement of penile curvature in Peyronie's disease patients: comparison of three methods.

Authors:  Michael Ohebshalom; John Mulhall; Patricia Guhring; Marilyn Parker
Journal:  J Sex Med       Date:  2007-01       Impact factor: 3.802

Review 5.  [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

Authors:  H Porst; K Hell-Momeni; H Büttner
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

6.  A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease.

Authors:  Savino M Di Stasi; Antonella Giannantoni; Robert L Stephen; Giovanni Capelli; Arcangelo Giurioli; Emmanuele A Jannini; Giuseppe Vespasiani
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

7.  Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.

Authors:  Marcus M Ilg; Marta Mateus; William J Stebbeds; Uros Milenkovic; Nim Christopher; Asif Muneer; Maarten Albersen; David J Ralph; Selim Cellek
Journal:  Eur Urol       Date:  2018-10-19       Impact factor: 20.096

8.  Combination Therapy Of Tadalafil And Pentoxifylline In Severe Erectile Dysfunction; A Prospective Randomized Trial.

Authors:  Santosh Kumar; Rajesh Roat; Swati Agrawal; Kumar Jayant; Ravimohan S Mavuduru; Shrawan Kumar
Journal:  Pol Przegl Chir       Date:  2015-08

9.  Current and emerging treatment options for Peyronie's disease.

Authors:  Ahmet Gokce; Julie C Wang; Mary K Powers; Wayne Jg Hellstrom
Journal:  Res Rep Urol       Date:  2013-01-14

10.  Perinatal characteristics and early childhood follow up after ex-utero intrapartum treatment for head and neck teratomas by prenatal diagnosis.

Authors:  Alireza A Shamshirsaz; Soroush Aalipour; Kelsey A Stewart; Ahmed A Nassr; Betul Y Furtun; Hadi Erfani; Nathan C Sundgren; Magdalena S Cortes; Roopali V Donepudi; Timothy C Lee; Deepak K Mehta; Elizabeth S Kravitz; Nazli M Asl; Jimmy Espinoza; Michael A Belfort
Journal:  Prenat Diagn       Date:  2021-02-09       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.